A healthy investment in healthier futures.
Cryo-Cell has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC QB: symbol CCEL. We specialize in stem cell preservation for family use.
Cryo-Cell Reports Financial Results for Fiscal 2018
Cryo-Cell International, Inc. (OTCQB:CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal year ended November 30, 2018.
Read More
Cryo-Cell Reports Fiscal Third Quarter 2018 Financial Results
Cryo-Cell International, Inc. (OTCQB:CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2018.
Read More
Arthur Ellis and Brian Sheehy Join Cryo-Cell’s Board of Directors
Cryo-Cell International announces that Arthur Ellis, JD, Board President of the Uptown People’s Law Center, and Brian Sheehy, M.D. M.A. C.F.A., Founder and Managing Partner IsZo Capital, have joined the company’s board of directors.
Read More
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2018 Financial Results
Cryo-Cell International, Inc. (OTCQB:CCEL), the world’s first private cord blood bank to separate and store stem cells, in 1992, announced results for the fiscal second quarter ended May 31, 2018.
Read More
Cryo-Cell Consummates Acquistion of Cord:Use Assets and Extends Its Leadership Position into the Public Cord Blood Banking Arena
Cryo-Cell International announced that it has completed its acquisition of substantially all of the assets of CORD:USE Cord Blood Bank, Inc. (“CORD:USE”) for an upfront purchase price of $14,000,000 plus up to $200 million in potential cash earnouts related to the CORD:USE public cord blood inventory and additional stock earnouts based upon Cryo-Cell achieving certain milestones associated with the purchased assets.
Read More